TEL AVIV, Israel, March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida.  Dr. Mor's presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days.

Chemomab logo (PRNewsfoto/Chemomab Therapeutics, Ltd.)

Leerink Partners Global BioPharma Conference

Date:             

March 12, 2024

Time:             

10:40am ET

Venue:             

Fontainebleau Hotel

Format:         

Live presentation and webcast

Webcast Link:   

https://wsw.com/webcast/leerink33/cmmb/2189648

Information:   

LeerinkEvents@Leerink.com



About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical  and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-leerink-global-biopharma-conference-302079499.html

SOURCE Chemomab Therapeutics Ltd

Copyright 2024 PR Newswire

Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Chemomab Therapeutics Charts.
Chemomab Therapeutics (NASDAQ:CMMB)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Chemomab Therapeutics Charts.